These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 25627655

  • 1. STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade.
    Triplett TA, Tucker CG, Triplett KC, Alderman Z, Sun L, Ling LE, Akporiaye ET, Weinberg AD.
    Cancer Immunol Res; 2015 May; 3(5):526-35. PubMed ID: 25627655
    [Abstract] [Full Text] [Related]

  • 2. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis.
    Garrison K, Hahn T, Lee WC, Ling LE, Weinberg AD, Akporiaye ET.
    Cancer Immunol Immunother; 2012 Apr; 61(4):511-21. PubMed ID: 21971588
    [Abstract] [Full Text] [Related]

  • 3. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, Zhao W, Leow CC, Hollingsworth R.
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [Abstract] [Full Text] [Related]

  • 4. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.
    Clin Cancer Res; 2017 Oct 15; 23(20):6165-6177. PubMed ID: 28855348
    [Abstract] [Full Text] [Related]

  • 5. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
    Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE.
    Cancer Res; 2007 Mar 01; 67(5):2351-9. PubMed ID: 17332368
    [Abstract] [Full Text] [Related]

  • 6. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.
    Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P.
    Clin Cancer Res; 2019 Nov 01; 25(21):6406-6416. PubMed ID: 31371342
    [Abstract] [Full Text] [Related]

  • 7. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
    Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM.
    Clin Cancer Res; 2008 Jun 15; 14(12):3966-74. PubMed ID: 18559619
    [Abstract] [Full Text] [Related]

  • 8. Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted Immunotherapy.
    Emerson DA, Rolig AS, Redmond WL.
    Cancer Immunol Res; 2021 Apr 15; 9(4):430-440. PubMed ID: 33593794
    [Abstract] [Full Text] [Related]

  • 9. An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
    Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M.
    Clin Cancer Res; 2019 Nov 15; 25(22):6709-6720. PubMed ID: 31573956
    [Abstract] [Full Text] [Related]

  • 10. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
    Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, Ching K, Yang W, van Loon K, Boor PPC, Rakké YS, Noordam L, Doornebosch P, Grünhagen D, Verhoef K, Polak WG, IJzermans JNM, Ni I, Yeung YA, Salek-Ardakani S, Sprengers D, Kwekkeboom J.
    J Immunother Cancer; 2020 Sep 15; 8(2):. PubMed ID: 32900860
    [Abstract] [Full Text] [Related]

  • 11. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH.
    J Immunother; 2010 Apr 15; 33(3):225-35. PubMed ID: 20445343
    [Abstract] [Full Text] [Related]

  • 12. Rationale for anti-OX40 cancer immunotherapy.
    Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A.
    Eur J Cancer; 2016 Jan 15; 52():50-66. PubMed ID: 26645943
    [Abstract] [Full Text] [Related]

  • 13. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
    Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y.
    Clin Cancer Res; 2010 Feb 15; 16(4):1191-205. PubMed ID: 20145179
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K, Kojima Y, Uno T, Hayakawa Y, Teng MW, Yoshizawa H, Yagita H, Gejyo F, Okumura K, Smyth MJ.
    J Immunol; 2010 May 15; 184(10):5493-501. PubMed ID: 20400706
    [Abstract] [Full Text] [Related]

  • 15. Science gone translational: the OX40 agonist story.
    Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD.
    Immunol Rev; 2011 Nov 15; 244(1):218-31. PubMed ID: 22017441
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.
    Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD.
    J Immunother; 2010 Oct 15; 33(8):798-809. PubMed ID: 20842057
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.
    Clin Cancer Res; 2006 Nov 15; 12(22):6808-16. PubMed ID: 17121902
    [Abstract] [Full Text] [Related]

  • 18. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.
    Clin Cancer Res; 2013 Nov 15; 19(22):6151-62. PubMed ID: 24030703
    [Abstract] [Full Text] [Related]

  • 19. Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy.
    Gough MJ, Killeen N, Weinberg AD.
    Immunology; 2012 Aug 15; 136(4):437-47. PubMed ID: 22578109
    [Abstract] [Full Text] [Related]

  • 20. OX40 is a potent immune-stimulating target in late-stage cancer patients.
    Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD.
    Cancer Res; 2013 Dec 15; 73(24):7189-7198. PubMed ID: 24177180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.